Tickerplace logo

Tickerplace

Allogene Therapeutics, Inc. logo

ALLOAllogene Therapeutics, Inc.

ALLO Stock Price, Valuation & Chart | Allogene Therapeutics, Inc.

Compare
$1.980-0.01 (-0.25%)

At close · 02 Sept 2026, 08:00 pm

Sector: HealthcareIndustry: BiotechnologyALLO intrinsic valueALLO calculated fair value vs price
OverviewFinancialsDividendsRatios

ALLO Historical price chart

ALLO Key Stats

Fair Value
Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock
Market Capitalization683.41M
PE Ratio-2.96
EPS-0.67
Trading Volume5.39M
Today's High/Low2.04/1.91
Dividend Yield0.00
52 Week High/Low4.46/1.04
Shares Outstanding345.15M
ALLO Financial Statement
ALLO Analyst ratings
ALLO Analysis & performance metrics

ALLO Company profile

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of…

ALLO Management team

Management
Earl M. Douglas Esq.
Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary
Christine Cassiano
Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer
Annie Yoshiyama
SVice President & Corporate Controller
Arie S. Belldegrun F.A.C.S., M.D.
Co-Founder & Executive Chairman
Geoffrey M. ParkerCFO
Executive Vice President & Chief Financial Officer
David D. Chang M.D., Ph.D.CEO
Co-Founder, President, Chief Executive Officer & Director
Zachary J. Roberts M.D., Ph.D.
Executive Vice President of Research & Development and Chief Medical Officer
Benjamin M. Beneski
Senior Vice President & Chief Technical Officer
Total 8 executives

ALLO Frequently asked questions

What is Allogene Therapeutics, Inc. (ALLO) Stock Price?

Current stock price of Allogene Therapeutics, Inc. (ALLO) stock is $1.980. The stock price is -0.25% lower in the session. The intraday range can be seen from this page. Volume of Allogene Therapeutics, Inc. (ALLO) stock is 5.39M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Allogene Therapeutics, Inc. (ALLO) stock price going up or down today?

The stock price of Allogene Therapeutics, Inc. (ALLO) can change with earnings, company news, and overall market sentiment. Allogene Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Allogene Therapeutics, Inc. stock expensive at its current price?

Whether Allogene Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ALLO on this page is -2.96. EPS on this page is -0.67. Compare those figures with peers and growth expectations before deciding if the current Allogene Therapeutics, Inc. price is justified.

How has the stock price of Allogene Therapeutics, Inc. (ALLO) performed historically?

Historical performance for Allogene Therapeutics, Inc. (ALLO) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ALLO reacted to past earnings and market events.

Should I buy Allogene Therapeutics, Inc. (ALLO) stock, at this price?

Buying Allogene Therapeutics, Inc. (ALLO) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.